Kraj: Kanada
Język: angielski
Źródło: Health Canada
ETIDRONATE DISODIUM; CALCIUM (CALCIUM CARBONATE)
SANIS HEALTH INC
M05BB01
ETIDRONIC ACID AND CALCIUM, SEQUENTIAL
400MG; 500MG
TABLET
ETIDRONATE DISODIUM 400MG; CALCIUM (CALCIUM CARBONATE) 500MG
ORAL
100
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0241781001; AHFS:
CANCELLED POST MARKET
2017-07-31
Page 1 of 31 _ _ _ _ _ _ PRODUCT MONOGRAPH PR ETIDROCAL Etidronate Disodium Tablets USP 400 mg and Calcium Carbonate Tablets USP 1,250 mg calcium carbonate per tablet (equivalent to 500 mg elemental calcium) BONE METABOLISM REGULATOR Sanis Health Inc. 333 Champlain Drive, Suite 102 Dieppe, New Brunswick E1A 1P2 Submission Control No: 154838 Date of Revision: May 10, 2012 Page 2 of 31 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS................................................................................. 4 ADVERSE REACTIONS................................................................................................... 6 DRUG INTERACTIONS ................................................................................................... 8 DOSAGE AND ADMINISTRATION ............................................................................... 9 OVERDOSAGE ............................................................................................................... 11 ACTIONS AND CLINICAL PHARMACOLOGY ......................................................... 11 STORAGE AND STABILITY......................................................................................... 14 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 14 PART II: SCIENTIFIC INFORMATION ............................................................................... 15 CLINICAL TRIALS......................................................................................................... 16 DETAILED PHARMACOLOGY ............................................................................ Przeczytaj cały dokument